Navigation Links
Biotech Posts Weak Performance in April
Date:5/3/2010

SAN FRANCISCO, May 3 /PRNewswire/ -- Despite the pop in the shares of Dendreon on the announcement that its prostate cancer therapy Provenge had finally been approved by the FDA, the biotech sector failed to build on that event and turned in a lackluster performance for the month with the Burrill Biotech Select Index dropping 2 percent in April. Not helping the cause was the fact that several companies including Amgen and Gilead Sciences cut their profit forecasts citing the impact of costs from U.S. healthcare reform in their outlooks. Gilead closed the month down almost 13 percent. Although the company reported a 45 percent jump in quarterly profit it lowered its full-year revenue forecast due to the recently passed health care reform legislation. They said its impact will be felt mostly in the company's HIV treatment business. Amgen, whose shares fell 3.6 percent in April, estimated that going forward, healthcare reform would trim annual U.S. sales revenue by 5 percent to 6 percent and $200 million to $250 million this year.

The new U.S. healthcare law calls on drug companies to offer higher price rebates for government funded health plans and will eventually require them to pay a fee based on their market share of the public plans. Some of the changes went into effect at the beginning of the year and all will be phased in by January 1, 2014.

"The industry convenes in Chicago this week for BIO 2010, where over 18,000 delegates from around the world are expected to attend, and despite April's performance of the 'blue-chip biotech companies, the sector is certainly in much better shape than it was one year ago when BIO 2009 was held in Atlanta," said G. Steven Burrill, CEO, Burrill & Company, a San Francisco based global leader in life sciences with activities in private equity, venture capital, merchant banking and media. "We are beginning to see signs of investor confidence return with capital markets rebounding.

"In the past year ten biotech IPOs have been completed with seven of these going out in the past four months, which is certain good news although investors continue to be selective," added Burrill. "The mood at this year's BIO convention will certainly be more upbeat than last year."

Busy month for IPOs

Three biotech companies priced their IPOs this month:  

  • Tengion completed its IPO, pricing well below its initial range. The Pennsylvania-based regenerative medicine company, which is focused on growing replacement organs from a patient's own cells, raised $30 million by offering 6 million shares at $5. In its first filing in December 2009, the company had targeted raising $40.25 million, which it raised to $46 million in an amended filing in mid-March. At that time it planned to sell 4.4 million shares at a range of $8 to $10.
  • Codexis raised $78 million through the sale of 6 million shares at $13 a share. Although the company priced at the low end of its range, shares ended the month at $13.62, 5 percent above their initial offering price. The Redwood City, California-based biotech develops biocatalysts used in the production of pharmaceuticals and renewable fuels and chemicals.
  • Alimera Sciences priced at $11 a share, 29 percent below its target range of $15 to $17, raising $72 million. The Alpharetta, Georgia-based biotech's late-stage lead compound is a treatment for diabetic macular edema.

(For full details of the performance of the biotech IPOs see: www.burrillreport.com/article-2295.html)

BY THE NUMBERS

(Compiled by the Burrill Report*)

  • The industry closed the month with a collective market cap of $382 billion (no change for the month)
  • 56 biotech companies (18.6 percent) have market caps greater than $1B (compared to 49 companies at the same time last year)
  • The Burrill Biotech Select Index is up 5.6 percent year-to-date

(*The April edition of the Burrill Report has a breakdown of the industry's Q1 2010 performance and copies are available on request.)

About Burrill & Company

Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. Burrill is also the creator, sponsor and facilitator of leading industry conferences worldwide and publisher of a range of bio-intelligence reports including the monthly Burrill Report (www.burrillreport.com) and annual "State of the Industry" report, the latest of which has just been released entitled Biotech 2010-Life Sciences: Adapting for Success.


'/>"/>
SOURCE Burrill & Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
4. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
5. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
6. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
7. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
8. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
9. Hawaii Biotech Receives Allowance to Perform West Nile Vaccine Clinical Trials
10. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
11. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)...  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... stages of an IPO. The United States ... cost of a prescription epilepsy drug being $450.00-$1200.00 for a one month ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion on ...
(Date:8/15/2017)... 2017  AOTI Inc. announced today that its fully owned ... opened a New York City Office in Yonkers, New ... Topical Wound Oxygen (TWO 2 ) homecare therapy. This new East ... Health Care (ACHC) under the company,s DMEPOS accreditation for Home/Durable Medical ... Advanced Oxygen ...
(Date:8/11/2017)... Aug. 11, 2017 DarioHealth Corp. (NASDAQ: DRIO), ... and big data solutions, today announced that it will ... 14 and host a conference call at 9:00am ET. ... and financial results and its strategy and outlook for ... by Erez Raphael , Chief Executive Officer, and ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... Radabaugh & Associates, a ... communities in North-Central West Virginia, is embarking on a cooperative charity effort with ... area. , The Chestnut Mountain Ranch (CMR) is a Christ-centered boarding school for ...
(Date:8/18/2017)... TX (PRWEB) , ... August 18, 2017 , ... ... management and financial planning firm that serves residential and commercial clients in the ... charity drive to raise community support for the fight against cancer. , Founded ...
(Date:8/18/2017)... ... August 18, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... the veil on false teachings pertaining to the mother of the Savior whom the world ... a far different picture of the role of this historical woman. , “The world ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Our Mountains to Climb: ... of a couple that grew stronger together through the faith they shared to overcome ... Trials” is the creation of published author, Barbara J. Corcoran, a retired teacher and ...
(Date:8/18/2017)... ... ... Super Heroes of the Bible”: a gripping and potent text that uses the ... may have on the reader’s life. “Depressed: Super Heroes of the Bible” is the ... of her time enjoying nature and her family in West Virginia. , Linhart ...
Breaking Medicine News(10 mins):